Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Enhanced Responses to Fostamatinib As Second-Line Therapy and in Persistent Immune Thrombocytopenia (ITP) Patients

Ralph Boccia, MD, Michael A. Boxer, MD, Waleed Ghanima, MD PhD, Quentin A. Hill, Michelle Sholzberg, MDBSc,FRCPC,MSc, Michael D. Tarantino, MD, Yuliya Kreychman, PharmD, Robert P. Numerof, PhD, Brian Olender, BA, Leslie Todd, Sandy Tong, MD, Anne-Marie Duliege, MDMS, Nichola Cooper, MD MRCP, James B. Bussel, MD

Blood (2019) 134 (Supplement_1): 1069.

https://doi.org/10.1182/blood-2019-126473

Published: 2019

Journal Articles

Impact of Parenteral Iron Therapy on Hemoglobin Normalization: A Retrospective Analysis

Chris LaVallee, M.S, Patrick Cronin, M.A, Isha Bansal, M.S, Jackie Kwong, PhD PharmD, Ralph Boccia, MD

Blood (2019) 134 (Supplement_1): 3445.

https://doi.org/10.1182/blood-2019-125793

Published: 2019

Journal Articles

Renal Response in Carfilzomib (K)- Versus Bortezomib (V)-Treated Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) in the Real-World Practice Setting

Shaji K. Kumar, MD, Alan Fu, PhD MPH, Khalid Mezzi, Megan Braunlin, Christopher Kim, PhD, Karim Iskander, Ruben Niesvizky, MD, Sundar Jagannath, MD, Ralph Boccia, MD, Noopur Raje, MD

Blood (2018) 132 (Supplement 1): 3253.

https://doi.org/10.1182/blood-2018-99-113519

Published: 2018

Journal Articles

Two-Year Safety and Efficacy Outcomes with Fostamatinib in Adult Patients with Immune Thrombocytopenia (ITP): Open-Label Extension to Phase 3 Trial Program

Anne-Marie Duliege, MDMS, Donald M. Arnold, MD MSc, FRCPC, Ralph Boccia, MD, Michael Boxer, MD, Nichola Cooper, MRCP, Quentin A Hill, BSc, MBChB, MRCP, FRCPath, Darla K Liles, MD, Michelle Sholzberg, MDM, MSc, FRCPC, Hany Zayed, PhD, Sandra Tong, MD, James B. Bussel, MD

Blood (2018) 132 (Supplement 1): 736.

https://doi.org/10.1182/blood-2018-99-110482

Published: 2018

Journal Articles

Phase 1 Dose-Ranging Study of Oral Ezatiostat Hydrochloride (Telintra®, TLK199) in Combination with Lenalidomide (Revlimid®) in Patients with Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Azra Raza, MD, Naomi Galili, Ph.D., Deborah Mulford, MD, Scott E. Smith, MD, PhD, FACP, Gail Brown, MD, Lisa Meng, PhD, David P. Steensma, MD, Roger M. Lyons, MD, Ralph Boccia, MD, Mikkael A. Sekeres, MD, MS, Guillermo Garcia-Manero, Ruben A. Mesa, MD

Blood (2011) 118 (21): 2778.

https://doi.org/10.1182/blood.V118.21.2778.2778

Published: 2011

Journal Articles

Iron Deficiency Anemia and Chronic Renal Insufficiency In An Oncology Population

Ralph Boccia, MD, Betsy Lahue, MPH, Robert Hauser, PharmD, PhD, Jessica Dioguardi, RPh

Blood (2010) 116 (21): 5152.

https://doi.org/10.1182/blood.V116.21.5152.5152

Published: 2010

Journal Articles

The Effects of Romiplostim or Standard of Care (SOC) on Splenectomy and Treatment Failure of Patients Who Had Immune Thrombocytopenia (ITP) for Less Than or Equal to One Year.

Ralph Boccia, MD, David J. Kuter, MD, DPhil, Mathias J. Rummel, MD, PhD, B. Gail Macik, MD, Ingrid Pabinger, MD, Dominik Selleslag, MD, Francesco Rodeghiero, MD, Beng Chong, MBBS, PhD, Xuena Wang, PhD, Richard Lizambri, MD

Blood (2010) 116 (21): 3702.

https://doi.org/10.1182/blood.V116.21.3702.3702

Published: 2010

Journal Articles

Preliminary Results of a Phase II Trial of Panobinostat (LBH589) In Refractory Myelodysplastic Syndromes (MDS) Patients

Ian W. Flinn, MD, PhD, Evan Lang, MD, Eric Raefsky, MD, Ralph Boccia, MD, Inés M. Macias-Pérez, PhD, Howard A. Burris, III, MD, John D. Hainsworth, MD

Blood (2010) 116 (21): 4015.

https://doi.org/10.1182/blood.V116.21.4015.4015

Published: 2010

Journal Articles

Forodesine, a Purine Nucleoside Phosphorylase (PNP) Inhibitor, Shows Clinical Activity In a Phase 2 Trial In Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL) – Interim Analysis

Taimur Sher, MD, Jose Azar, MD, Stephen Spurgeon, MD, John Catalano, MBBS, FRACP, FRCPA, Richard R. Furman, MD, Miles Prince, MD, FRACP, FRCPA, Nancy L. Bartlett, MD, Simon Durrant, MBBS, FRCP, FRCPath, Ralph Boccia, MD, Aisha Masood, MD, Scott Lyman, MS, Jean Cantey-Kiser, William P Sheridan, MB, BS, Asher Chanan-Khan, MD

Blood (2010) 116 (21): 1397.

https://doi.org/10.1182/blood.V116.21.1397.1397

Published: 2010

Journal Articles

An Open-Label Phase 1/2 Trial of Bendamustine Combined with Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma

James R. Berenson, MD, Ori Yellin, MD, Alberto Bessudo, MD, Ralph Boccia, MD, Donald S. Gravenor, MD, Stephen J. Noga, MD, PhD, Robert S Siegel, MD, Regina A. Swift, RN, Michael D Ehrman, MS, Debra Bensen-Kennedy, MD

Blood (2010) 116 (21): 3057.

https://doi.org/10.1182/blood.V116.21.3057.3057

Published: 2010

Journal Articles

Phase 2 Randomized Multicenter Study of Extended Dosing Schedules of Oral Ezatiostat HCl (Telintra), a Glutathione Analog Prodrug GSTP1-1 Inhibitor, In Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Azra Raza, MD, Naomi Galili, Ph.D., Scott Smith, MD, PhD, FACP, John E. Godwin, MD, MS, Ralph Boccia, MD, Han Myint, MD, Daruka Mahadevan, MD, PhD, Deborah Mulford, MD, Mark Rarick, MD, Mary Ann Allison, MD, Ostap Melnyk, MD, Lisa Meng, Marsha Jones, MD, Gail Brown, MD, Shelby A Young, RN, BSN, Mikkael A. Sekeres, MD, MS

Blood (2010) 116 (21): 2910.

https://doi.org/10.1182/blood.V116.21.2910.2910

Published: 2010

NARROW

Enhanced Responses to Fostamatinib As Second-Line Therapy and in Persistent Immune Thrombocytopenia (ITP) Patients

Impact of Parenteral Iron Therapy on Hemoglobin Normalization: A Retrospective Analysis

Renal Response in Carfilzomib (K)- Versus Bortezomib (V)-Treated Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) in the Real-World Practice Setting

Two-Year Safety and Efficacy Outcomes with Fostamatinib in Adult Patients with Immune Thrombocytopenia (ITP): Open-Label Extension to Phase 3 Trial Program

Phase 1 Dose-Ranging Study of Oral Ezatiostat Hydrochloride (Telintra®, TLK199) in Combination with Lenalidomide (Revlimid®) in Patients with Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Iron Deficiency Anemia and Chronic Renal Insufficiency In An Oncology Population

The Effects of Romiplostim or Standard of Care (SOC) on Splenectomy and Treatment Failure of Patients Who Had Immune Thrombocytopenia (ITP) for Less Than or Equal to One Year.

Preliminary Results of a Phase II Trial of Panobinostat (LBH589) In Refractory Myelodysplastic Syndromes (MDS) Patients

Forodesine, a Purine Nucleoside Phosphorylase (PNP) Inhibitor, Shows Clinical Activity In a Phase 2 Trial In Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL) – Interim Analysis

An Open-Label Phase 1/2 Trial of Bendamustine Combined with Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma

Phase 2 Randomized Multicenter Study of Extended Dosing Schedules of Oral Ezatiostat HCl (Telintra), a Glutathione Analog Prodrug GSTP1-1 Inhibitor, In Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only